Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MMP1 | P03956 | 7/20 | 0.46 |
| ▸ | MMP2 | P08253 | 7/20 | 0.46 |
| ▸ | MMP9 | P14780 | 7/20 | 0.46 |
| ▸ | EGFR | P00533 | 5/20 | 0.46 |
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1367511 | 1.00 | BTK (0.60) | BTKNPC1RAB9AMEN1KMT2A | |
| SCHEMBL27755013 | 0.87 | BTK (0.45) | BTKNPC1RAB9AMEN1KMT2A | |
| SCHEMBL1367567 | 0.85 | NPC1 (0.52) | BTKNPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL1136434 | 0.84 | BTK (0.57) | BTKNPC1RAB9AMEN1KMT2A | |
| SCHEMBL1136433 | 0.84 | BTK (0.57) | BTKNPC1RAB9AMEN1KMT2A | |
| SCHEMBL1367507 | 0.82 | BLK (0.58) | BTKNPC1RAB9AMEN1KMT2A | |
| SCHEMBL1367950 | 0.81 | BTK (0.61) | BTKNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1136426 | 0.79 | BTK (0.52) | BTKNPC1RAB9AMEN1KMT2A | |
| SCHEMBL1136425 | 0.79 | BTK (0.52) | BTKNPC1RAB9AMEN1KMT2A | |
| SCHEMBL1136399 | 0.78 | BTK (0.53) | BTKNPC1RAB9AEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067599-B2 | Imidazo [4,5-B] pyridine and pyrrolo [2,3-B] pyridine protein kinase inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2011-11-29 | — | — | US | claimed |
| US-20090318428-A1 | HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | HOFFMANN-LA ROCHE, INC. | 2009-12-24 | — | — | US | claimed |
| US-8067599-B2 | Imidazo [4,5-B] pyridine and pyrrolo [2,3-B] pyridine protein kinase inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20090318428-A1 | HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | HOFFMANN-LA ROCHE, INC. | 2009-12-24 | — | — | US | disclosed |
| EP-2064213-A1 | HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008028617-A1 | HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318428-A1 | HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | MAP3K5, MAP3K1, PRKACA | BTK 334/4885NPC1 1424/4885RAB9A 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.